Highlights Newsletter 3
This newsletter presents you the following key sessions:
1. Podcast with Prof. Dr. Nicholas Short about the efficacy of Ponatinib and Blinatumomab for the treatment of
patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
2. Matched propensity scoring suggests a higher efficacy, with increased toxicity for axicabtagene ciloleucel vs.
tisagenlecleucel in the treatment of relapsed/refractory diffuse-large B-cell lymphoma
3. Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3-mutated AML
4. Lisocabtagene maraleucel effective as second-line therapy for R/R large B-cell lymphoma in patients not
intended for transplantation
5. Time-limited venetoclax-obinutuzumab with or without ibrutinib superior to chemo-immunotherapy in
frontline CLL